ALVO Investigation: Investors Encouraged to Contact Kirby McInerney LLP

Core Viewpoint - Alvotech is under investigation by Kirby McInerney LLP for potential violations of federal securities laws following a significant decline in its stock price after receiving a complete response letter from the FDA regarding its biologics license application for AVT05 [1][2]. Company Summary - Alvotech (NASDAQ: ALVO) experienced a stock price drop of $2.62 per share, approximately 34.25%, from $7.65 on October 31, 2025, to $5.03 on November 3, 2025, after the FDA issued a complete response letter related to a failed facility inspection [1]. Legal Context - Kirby McInerney LLP is conducting an investigation on behalf of Alvotech investors concerning possible unlawful business practices by the company or its senior management [1][2]. - The law firm specializes in securities litigation and has a history of achieving recoveries totaling billions of dollars for shareholders [3].